Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's innovative TrueGlue platform. Read more here.
One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...
FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of countless patients with rare diseases by modernizing and streamlining the FDA ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...
The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Tourmaline Bio (TRML – Research Report) today. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback